文献速递淋巴瘤

慢性淋巴细胞白血病中假性缺氧与自分泌嘌呤能信号介导的T细胞功能障碍

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用B细胞恶性细胞系与人外周血单个核细胞建立癌症诱导T细胞功能障碍模型,发现慢性淋巴细胞白血病(CLL)来源细胞系(PGA-1、CII、Mec-1)而非其他B细胞恶性肿瘤细胞系,通过产生假性缺氧状态改变T细胞代谢组,使T细胞滞留于有氧糖酵解而无法切换至氧化磷酸化(OXPHOS),并产生免疫抑制性腺苷抑制T细胞活化,阻断腺苷受体可恢复功能;原代CLL样本的自体T细胞亦存在类似缺氧样特征,体外去除CLL细胞及体内以维奈克拉联合奥妥珠单抗降低白血病负荷后假性缺氧可逆转并恢复T细胞功能。

要点

  • CLL来源细胞系(PGA-1、CII、Mec-1)而非其他B细胞恶性细胞系,使T细胞产生假性缺氧并滞留于有氧糖酵解。
  • T细胞产生免疫抑制性腺苷,阻断腺苷受体可恢复其活化。
  • 体内以维奈克拉联合奥妥珠单抗降低白血病负荷后假性缺氧可逆转并恢复T细胞功能。

核心结论

  • 研究揭示了CLL中与T细胞功能障碍相关的假性缺氧程序,调节缺氧与嘌呤能通路可能有助于治疗性恢复T细胞功能。

研究设计与样本

  • 研究使用B细胞恶性细胞系与人外周血单个核细胞建立癌症诱导T细胞功能障碍模型,并在原代CLL样本的自体T细胞中验证。

主要发现

  • CLL来源细胞系(PGA-1、CII、Mec-1)而非其他B细胞恶性细胞系,通过产生假性缺氧状态改变T细胞代谢组。
  • T细胞滞留于有氧糖酵解,无法切换至氧化磷酸化(OXPHOS)。
  • T细胞产生免疫抑制性腺苷,通过抑制活化对功能产生负面影响,阻断腺苷受体可恢复功能。
  • 原代CLL样本的自体T细胞存在类似的缺氧样特征。
  • 体外去除CLL细胞后及体内以维奈克拉联合奥妥珠单抗降低白血病负荷后,假性缺氧可逆转并恢复T细胞功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired T-cell dysfunction is common in chronic B-cell malignancies. Given the strong connection between T-cell metabolism and function, we investigated metabolic alterations as the basis of T-cell dysfunction induced by malignant cells. Using B-cell malignant cell lines and human peripheral blood mononuclear cells, we first established a model that recapitulates major aspects of cancer-induced T-cell dysfunction. Cell lines derived from chronic lymphocytic leukemia (CLL) (PGA-1, CII, and Mec-1), but not from other B-cell malignancies, altered the T-cell metabolome by generating a pseudohypoxic state. T cells were retained in aerobic glycolysis and were not able to switch to oxidative phosphorylation (OXPHOS). Moreover, T cells produced immunosuppressive adenosine that negatively affected function by dampening the activation, which could be restored by the blocking of adenosine receptors. Subsequently, we uncovered a similar hypoxic-like signature in autologous T cells from primary CLL samples. Pseudohypoxia was reversible upon depletion of CLL cells ex vivo and, importantly, after the in vivo reduction of the leukemic burden with combination therapy (venetoclax and obinutuzumab), restoring T-cell function. In conclusion, we uncovered a pseudohypoxic program connected with T-cell dysfunction in CLL. Modulation of hypoxia and the purinergic pathway might contribute to therapeutic restoration of T-cell function.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Montironi C, Jacobs CF, Cretenet G, et al. T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia. Blood Adv. 2023. PMID: 37552122. doi:10.1182/bloodadvances.2023010305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。